ArticleJournal of the American Chemical Society2018
Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways.
Article in Journal of the American Chemical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- Antiosteolytic Bisphosphonate Metallodrug Coordination Networks: Dissolution Profiles andACS applied bio materials · 2025Article
- Microbial Squalene: A Sustainable Alternative for the Cosmetics and Pharmaceutical Industry - A Review.Engineering in life sciences · 2024Review
- The Functional Interaction of KATP and BK Channels with Aquaporin-4 in the U87 Glioblastoma Cell.Biomedicines · 2024Article
- Alendronate augments lipid A‑induced IL‑1β release by ASC‑deficient RAW264 cells via AP‑1 activation.Experimental and therapeutic medicine · 2023Article
- The ATP-dependent Pathways and Human Diseases.Current medicinal chemistry · 2023Article
- Compartmentalization and transporter engineering strategies for terpenoid synthesis.Microbial cell factories · 2022Review
- How zoledronic acid improves osteoporosis by acting on osteoclasts.Frontiers in pharmacology · 2022Review
- Synthesis of the biologically important dideuterium-labelled adenosine triphosphate analogue ApppI(Beilstein journal of organic chemistry · 2022Article
- Endocrinal metabolic regulation on the skeletal system in post-menopausal women.Frontiers in physiology · 2022Review
- Alendronate Augments Lipid A-Induced IL-1α Release via Activation of ASC but Not Caspase-11.Inflammation · 2021Article
- Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive KPharmaceutics · 2021Article
- Tissue-Nonspecific Alkaline Phosphatase (TNAP) as the Enzyme Involved in the Degradation of Nucleotide Analogues in the Ligand Docking and Molecular Dynamics Approaches.Biomolecules · 2021Article
- Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury.Scientific reports · 2021Article
- The Antitumor Effect of Lipophilic Bisphosphonate BPH1222 in Melanoma Models: The Role of the PI3K/Akt Pathway and the Small G Protein Rheb.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Bisphosphonates are a major class of drugs used to treat osteoporosis, Paget's disease, and cancer. They have been proposed to act by inhibiting one or more targets including protein prenylation, the epidermal growth factor receptor, or the adenine nucleotide translocase. Inhibition of the latter is due to formation in cells of analogs of ATP: the isopentenyl ester of ATP (ApppI) or an AppXp-type analog of ATP, such as AMP-clodronate (AppCCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.